On the impact of the CYP2D6 ultra-rapid metabolizer genotype on mirtazapine pharmacokinetics.

被引：0
|
作者：
Brockmöller, J
Kirchheiner, J
Henckel, H
Meineke, I
Roots, I
机构：
[1] Univ Gottingen, D-3400 Gottingen, Germany
[2] Humboldt Univ, D-1086 Berlin, Germany
[3] Charite Med Ctr, Berlin, Germany
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2003.11.250
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P67 / P67
页数：1
相关论文
共 50 条
  • [41] Supervised Classification of CYP2D6 Genotype and Metabolizer Phenotype With Postmortem Tramadol-Exposed Finns
    Wendt, Frank R.
    Novroski, Nicole M. M.
    Rahikainen, Anna-Liina
    Sajantila, Antti
    Budowle, Bruce
    AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY, 2019, 40 (01): : 8 - 18
  • [42] Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects
    Myo-Kyoung Kim
    Joo-Youn Cho
    Hyeong-Seok Lim
    Kyoung-Seop Hong
    Jae-Yong Chung
    Kyun-Seop Bae
    Dal-Seok Oh
    Sang-Goo Shin
    Sang-Hun Lee
    Dong-Ho Lee
    Bumchan Min
    In-Jin Jang
    European Journal of Clinical Pharmacology, 2003, 59 : 111 - 116
  • [43] Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects
    Kim, MK
    Cho, JY
    Lim, HS
    Hong, KS
    Chung, JY
    Bae, KS
    Oh, DS
    Shin, SG
    Lee, SH
    Lee, DH
    Min, B
    Jang, IJ
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (02) : 111 - 116
  • [44] The effect of CYP2D6 genotype on the pharmacokinetics of lovastatin in Chinese subjects.
    Yin, OQ
    Chang, Q
    Tomlinson, B
    Chow, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P18 - P18
  • [45] Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects
    Gan, SH
    Ismail, R
    Adnan, WAW
    Wan, Z
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 30 (02) : 189 - 195
  • [46] The Impact of CYP2D6 metabolizer phenotypes on the EDDP/methadone metabolic ratio: A comprehensive analysis
    Wilmes, Verena
    Kettner, Mattias
    Corvest, Eva
    Verhoff, Marcel A.
    Kauferstein, Silke
    FORENSIC SCIENCE INTERNATIONAL, 2025, 370
  • [47] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [48] Molecular analysis of the CYP2D6*41 "intermediate metabolizer" allele
    Toscano, C
    Raimundo, S
    Klein, K
    Schaeffeler, E
    Eichelbaum, M
    Schwab, M
    Zanger, UM
    DRUG METABOLISM REVIEWS, 2004, 36 : 116 - 116
  • [49] Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
    Susce, Margaret T.
    Murray-Carmichael, Elaina
    de Leon, Jose
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (07): : 1356 - 1358
  • [50] CYP2D6 genotype and tamoxifen response
    James M Rae
    Matthew P Goetz
    Daniel F Hayes
    James N Ingle
    Lang Li
    Anna Maria Storniolo
    Vered Stearns
    David A Flockhart
    Breast Cancer Research, 7
12345